Table 1. Patients’ characteristics (n=38).

Variables	Median (range)/frequency (%)
Age [years]	58.6 [40-75]
Sex
Male	15 (39.5)
Female	23 (60.5)
Smoking status
Smoker	11 (28.9)
Never-smoker	27 (71.1)
Performance status
0-1	32 (84.2)
2	6 (15.8)
First-line chemotherapy
Pemetrexed plus cisplatin	22 (57.9)
Pemetrexed plus carboplatin	10 (26.3)
Pemetrexed single use	6 (15.8)
Icotinib treatment
Second line	27 (71.1)
Maintenance	11 (28.9)
Post-study treatment
Paclitaxel	12 (31.5)
Platinum	10 (26.3)
Docetaxel	9 (23.6)
Gemcitabine	8 (21.0)
None	6 (15.7)
Other EGFR-TKIs	6 (15.7)

EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors.